Why AstraZeneca May Be 2025s Most Underrated Pharma Stock
…
92,830$
0,26%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Swedish Business Consortium to build AI Factory with NVIDIA
· AstraZeneca, Ericsson, Saab, SEB and Wallenberg Investments to tap new sovereign AI infrastructure
· NVIDIA to open AI…
AstraZeneca CEO gains shares under performance plan By Investing.com
AstraZeneca CEO gains shares under performance plan…
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust
Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust are part of the Zacks top Analyst Blog.…
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AZNs key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.…
Top Research Reports for Visa, AstraZeneca & Shell
Todays Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and Shell…
FTSE 100 LIVE: Stocks rise on US-China hopes, miners rally whilst AstraZeneca tumbles
FTSE starts higher Traders hopeful after US-China talks Miners rally Drug makers tumble on Trump post AstraZeneca falls 5% GSK…
FTSE 100 LIVE: Index starts higher on US-China hopes, miners rally whilst AstraZeneca tumbles
FTSE starts higher Traders hopeful after US-China talks Miners rally Drug makers tumble on Trump post AstraZeneca falls 5% GSK…
FTSE 100 LIVE: Index starts higher, AstraZeneca and GSK hit by Trump social post
FTSE starts higher Traders hopeful after US-China talks Drug makers tumble on Trump post AstraZeneca falls 5% GSK down 3%…
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after…
Roche Underweight
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Roche auf "Underweight" mit einem Kursziel von 220 Franken belassen. Dass…
JPMorgan belässt Roche auf Underweight - Ziel 220 Franken
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Roche auf "Underweight" mit einem Kursziel von 220 Franken belassen. Dass…
AstraZeneca unveils new facility as part of multibillion-dollar investment in US manufacturing
AstraZeneca has opened its first U.S.-operated cell therapy manufacturing facility in Rockville, Maryland, as part of its ongoing $3.5 billion…
Think Its Too Late to Buy Tempus AI? Heres the Biggest Reason Why Theres Still Time.
When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like theyre standing on a dock watching…
Total Voting Rights
1 May 2025
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…